LifeVantage Corporation (LFVN) 株式分析

企業概要

LifeVantage Corporation is an international enterprise dedicated to the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management solutions, pre and pro-biotics, as well as skin and hair care products, with a flagship offering including the dietary supplement Protandim. The corporation operates within the Consumer Defensive sector, specifically the Packaged Foods industry, a classification that typically suggests products essential to daily consumption and offering a degree of resilience against economic downturns compared to discretionary spending categories. This entity employs a workforce of 232 individuals and holds a market capitalization of $51.48M, generating annual revenue of $210.05M. The combination of a market cap in the low single-digit billions range and a market capitalization of $51.48M indicates that LifeVantage operates as a small-cap entity within its sector, suggesting a position where the company is likely navigating growth challenges or market consolidation rather than established dominance in a mature, large-cap peer group.

財務健全性

The company reported a total revenue of $210.05M for the trailing twelve months, with a net income of $7.86M and an EBITDA of $11.77M. The significant gap between the revenue of $210.05M and the net income of $7.86M reveals a cost structure where operational expenses and taxes consume approximately 96.3% of top-line revenue, highlighting intense pressure on profitability despite high sales volume. While the EBITDA stands at $11.77M, the free cash flow is recorded at -$454,500, which indicates that the company is currently burning cash and lacks immediate financial flexibility to fund capital expenditures or dividends without external financing. Profitability is further segmented by margins that show a gross margin of 78.7%, an operating margin of 0.5%, and a profit margin of 3.7%. The high gross margin of 78.7% reflects strong pricing power or low cost of goods sold, whereas the negligible operating margin of 0.5% suggests that administrative and selling, general, and administrative expenses are nearly equal to operating profit before interest and taxes. The balance sheet presents a mixed picture with cash holdings of $10.18M against total debt of $10.69M, resulting in a debt-to-equity ratio of 32.41, which implies a leveraged capital structure where liabilities slightly exceed liquid assets. However, the current ratio stands at 2.03, indicating that the company possesses more than double the current assets required to cover its short-term liabilities, suggesting adequate short-term liquidity despite the net debt position. Return on Equity is calculated at 25.0% and return on assets is 8.5%, metrics that reveal management is generating substantial returns on shareholders' equity relative to the total asset base, though the high debt-to-equity ratio necessitates careful monitoring of interest coverage.

バリュエーション評価

Valuation metrics for LifeVantage Corporation indicate a trailing P/E ratio of 6.70 and a forward P/E of 6.55. The minimal difference between the trailing P/E of 6.70 and the forward P/E of 6.55 implies that the market does not expect a significant expansion in earnings trajectory in the near future, as the forward multiple is slightly lower than the historical average. The price-to-book ratio is stated at 1.56, which indicates that the market values the company at a modest premium of 56% over its book value, suggesting that investors assign some intangible value to the brand or intellectual property despite the earnings contraction. Alternative valuation metrics such as the price-to-sales ratio of 0.25 and an EV/EBITDA of 4.41 suggest the stock is priced very cheaply relative to its revenue and cash flow generation, often a characteristic of distressed or turnaround situations. Price metrics show a 52-week high of $15.37 and a 52-week low of $3.90, and while the current price is not explicitly provided in the source facts, the valuation multiples suggest the stock trades significantly below the 52-week high, reflecting the recent earnings decline. The beta value is 0.39, which explains that the stock price volatility is substantially lower than the broader market, indicating that LifeVantage moves independently of general market swings and may offer stability during periods of high market volatility.

Growth & Income

Growth metrics show a revenue growth of -27.8% year-over-year and an earnings growth of -89.5% year-over-year. The earnings growth rate of -89.5% is declining much faster than the revenue growth rate of -27.8%, which implies that the decline in profitability is disproportionately severe compared to the decline in sales, likely due to the aforementioned compression in operating margins. The company offers a dividend yield of 4.5% with a payout ratio of 29.2%. The payout ratio of 29.2% is relatively low relative to the net income of $7.86M, which theoretically suggests the dividend could be sustainable even if earnings fluctuate, although the negative free cash flow of -$454,500 presents a potential risk to future dividend continuity. Given the negative earnings growth, the dividend yield acts as an income buffer rather than a signal of robust growth momentum. Overall, the growth and income profile is characterized by significant contraction in both revenue and earnings, supported by a high dividend yield but constrained by negative cash flow and a highly leveraged balance sheet.